The largest clinical study ever conducted to date of patients with advanced leukemia found that 88 percent achieved complete remissions after being treated with genetically modified versions of their own immune cells.
A collaborative effort among cancer experts from Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College has yielded an interesting association: Obesity prior to diagnosis is associated with a five-fold increase in the risk of death from early-stage squamous cell carcinoma of the tongue.
FoundationOne Heme was developed using technology, methods and computational algorithms developed by Foundation Medicine, combined with Memorial Sloan Kettering’s deep and vast expertise in clinical and laboratory research into hematologic malignancies.
Michael A. Foley, PhD, has been selected to lead the Tri-Institutional Therapeutics Discovery Institute, Inc., a pioneering collaboration of Weill Cornell Medical College, The Rockefeller University and Memorial Sloan Kettering Cancer Center.
Renowned cancer biologist Joan Massagué, PhD, has been named Director of the Sloan Kettering Institute, one of the most dynamic and robust cancer research programs in the United States, and the research arm of Memorial Sloan Kettering Cancer Center.
Memorial Sloan Kettering Cancer Center has announced the appointment of surgical oncologist Richard Barakat to the new position of Deputy Physician-in-Chief for the Memorial Sloan Kettering Regional Care Network and Alliance.
Memorial Sloan Kettering Cancer Center, The Rockefeller University and Weill Cornell Medical College have formed the pioneering Tri-Institutional Therapeutics Discovery Institute, Inc. and have partnered with Takeda Pharmaceutical Company, Ltd.